Day Zero Diagnostics, Inc., a Boston, MA-based infectious disease diagnostic company using genome sequencing and machine learning, completed an $8.6M Series A funding.
The round was led by Triventures, with participation from existing investors including Sands Capital Ventures and Golden Seeds. As part of the financing, Peter Fitzgerald, MD PhD, a Managing Partner at Triventures will join the Board of Directors.
The company intends to use the funds to accelerate prototype development of its sample preparation technology and computational approach, to introduce DZD Lab Services, a suite of sequencing based diagnostic services to allow clinicians to address critical infection situations and transmission events.
Founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital and led by Jong Lee, CEO, Day Zero Diagnostics is developing a sequencing-based rapid diagnostic that identifies, within hours, both the species and the antibiotic resistance profile of a bacterial pathogen. The company uses high throughput sequencing technologies and proprietary machine learning algorithms to rapidly predict pathogen species and drug resistance profiles.
Since its founding in 2016, Day Zero Diagnostics has been developing Blood2Bac™, a process for ultrahigh enrichment of bacterial DNA from complex clinical samples. It has also developed MicrohmDB® into a large databases that contains the whole genome sequences of pathogens along with their antibiotic resistance profiles. The dataset serves as a training resource for Keynome™, the company’s machine learning algorithm for predicting antibiotic resistance profiles from genomic sequences.